Verteporfin
Verteporfin is a photosensitizing medication belonging to the porphyrin derivative class. It is primarily used in photodynamic therapy to treat certain eye conditions, particularly wet age-related macular degeneration (AMD) and abnormal blood vessel growth beneath the retina. It works by accumulating in abnormal blood vessels and becoming activated when exposed to specific wavelengths of laser light. This produces reactive oxygen species that damage abnormal blood vessels and help prevent further leakage and vision loss. Verteporfin is administered through intravenous infusion, followed by controlled laser treatment of the affected eye. Common side effects include visual disturbances, injection-site reactions, headache, and photosensitivity. Serious adverse effects may include severe vision loss and infusion-related complications. Patients should avoid direct sunlight and bright indoor light for approximately five days after treatment to reduce the risk of photosensitivity reactions.
Verteporfin was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Verteporfin, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Verteporfin from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Verteporfin, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
